{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:28:11Z","timestamp":1787243291063,"version":"build-2736575974"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2KL2TR001856-06"],"award-info":[{"award-number":["2KL2TR001856-06"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI104895"],"award-info":[{"award-number":["R01AI104895"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI151362"],"award-info":[{"award-number":["R21AI151362"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03AI144636"],"award-info":[{"award-number":["R03AI144636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI151363"],"award-info":[{"award-number":["R21AI151363"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We evaluated the clinical characteristics and outcomes of patients with COVID-19 who received three-drug combination regimens for treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections during a single-centre outbreak. Our objective was to describe the clinical outcomes and molecular characteristics and in vitro synergy of antibiotics against CRAB isolates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Patients with severe COVID-19 admitted between April and July 2020 with CRAB infections were retrospectively evaluated. Clinical success was defined as resolution of signs\/symptoms of infection without need for additional antibiotics. Representative isolates underwent whole-genome sequencing (WGS) and in vitro synergy of two- or three-drug combinations was assessed by checkerboard and time-kill assays, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen patients with CRAB pneumonia or bacteraemia were included. Treatment regimens included high-dose ampicillin-sulbactam, meropenem, plus polymyxin B (SUL\/MEM\/PMB; 72%), SUL\/PMB plus minocycline (MIN; 17%) or other combinations (12%). Clinical resolution was achieved in 50% of patients and 30-day mortality was 22% (4\/18). Seven patients had recurrent infections, during which further antimicrobial resistance to SUL or PMB was not evident. PMB\/SUL was the most active two-drug combination by checkerboard. Paired isolates collected before and after treatment with SUL\/MEM\/PMB did not demonstrate new gene mutations or differences in the activity of two- or three-drug combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Use of three-drug regimens for severe CRAB infections among COVID-19 resulted in high rates of clinical response and low mortality relative to previous studies. The emergence of further antibiotic resistance was not detected phenotypically or through WGS analysis. Additional studies are needed to elucidate preferred antibiotic combinations linked to the molecular characteristics of infecting strains.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkad042","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T09:20:39Z","timestamp":1675761639000},"page":"1034-1040","source":"Crossref","is-referenced-by-count":22,"title":["Early initiation of three-drug combinations for the treatment of carbapenem-resistant\n                    <i>A. baumannii<\/i>\n                    among COVID-19 patients"],"prefix":"10.1093","volume":"78","author":[{"given":"Emily L","family":"Heil","sequence":"first","affiliation":[{"name":"Department of Practice, Science, and Health Outcomes Research, University of Maryland School of Pharmacy , 20 North Pine Street, Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly C","family":"Claeys","sequence":"additional","affiliation":[{"name":"Department of Practice, Science, and Health Outcomes Research, University of Maryland School of Pharmacy , 20 North Pine Street, Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen G","family":"Kline","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M","family":"Rogers","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M","family":"Squires","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Iovleva","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9620-2525","authenticated-orcid":false,"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Banoub","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Maryland Medical Center , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandee M","family":"Noval","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Maryland Medical Center , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Luethy","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Maryland School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-5665","authenticated-orcid":false,"given":"Ryan K","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Pittsburgh , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"2023070503450661500_dkad042-B1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Reviews"},{"key":"2023070503450661500_dkad042-B2","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1128\/AAC.01728-10","article-title":"Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections","volume":"55","author":"Esterly","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070503450661500_dkad042-B3","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01110-18","article-title":"New treatment options against carbapenem-resistant Acinetobacter baumannii infections","volume":"63","author":"Isler","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070503450661500_dkad042-B4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023070503450661500_dkad042-B5","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/civ048","article-title":"Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance","volume":"60","author":"Qureshi","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023070503450661500_dkad042-B6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01268-16","article-title":"High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model","volume":"61","author":"Lenhard","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070503450661500_dkad042-B7","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023070503450661500_dkad042-B8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01680-20","article-title":"Minocycline alone and in combination with polymyxin B, meropenem, and sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii in an in vitro pharmacodynamic model","volume":"65","author":"Beganovic","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070503450661500_dkad042-B9","doi-asserted-by":"crossref","first-page":"7236","DOI":"10.1128\/AAC.01669-16","article-title":"Population pharmacokinetics and pharmacodynamics modeling to optimize dosage regimens of sulbactam in critically ill patients with severe sepsis caused by Acinetobacter baumannii","volume":"60","author":"Jaruratanasirikul","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070503450661500_dkad042-B10","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Thirtieth Edition","author":"CLSI","year":"2020"},{"key":"2023070503450661500_dkad042-B11","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02759-21","article-title":"Carbapenem-resistant Acinetobacter baumannii in U.S. hospitals: diversification of circulating lineages and antimicrobial resistance","volume":"13","author":"Iovleva","year":"2022","journal-title":"mBio"},{"key":"2023070503450661500_dkad042-B12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cmb.2012.0021","article-title":"SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing","volume":"19","author":"Bankevich","year":"2012","journal-title":"J Comput Biol"},{"key":"2023070503450661500_dkad042-B13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4939-0554-6_12","article-title":"Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq","volume":"1151","author":"Deatherage","year":"2014","journal-title":"Methods Mol Biol"},{"key":"2023070503450661500_dkad042-B14","first-page":"D517","article-title":"CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database","volume":"48","author":"Alcock","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2023070503450661500_dkad042-B15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.diagmicrobio.2010.12.023","article-title":"High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen","volume":"70","author":"Shields","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023070503450661500_dkad042-B16","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1128\/AAC.01779-13","article-title":"In vitro responses of Acinetobacter baumannii to two- and three-drug combinations following exposure to colistin and doripenem","volume":"58","author":"Oleksiuk","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070503450661500_dkad042-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the national healthcare safety network, 2015\u20132017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023070503450661500_dkad042-B18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023070503450661500_dkad042-B19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023070503450661500_dkad042-B20","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1093\/ofid\/ofab466.835","article-title":"638. The impact of in vitro synergy between colistin and meropenem on clinical outcomes in invasive carbapenem-resistant gram-negative infections: a report from the OVERCOME trial","volume":"8","author":"Pogue","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023070503450661500_dkad042-B21","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/jac\/dkx002","article-title":"Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity","volume":"72","author":"Lenhard","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023070503450661500_dkad042-B22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023070503450661500_dkad042-B23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cmi.2018.01.015","article-title":"Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals","volume":"24","author":"Papst","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2023070503450661500_dkad042-B24","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.cmi.2020.03.035","article-title":"Colistin plus meropenem for carbapenem-resistant gram-negative infections: in vitro synergism is not associated with better clinical outcomes","volume":"26","author":"Nutman","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023070503450661500_dkad042-B25","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1128\/AAC.00342-13","article-title":"Pharmacodynamics modeling to optimize dosage regimens of sulbactam","volume":"57","author":"Jaruratanasirikul","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023070503450661500_dkad042-B26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jiac.2014.12.005","article-title":"Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections","volume":"21","author":"Yokoyama","year":"2015","journal-title":"J Infect Chemother"},{"key":"2023070503450661500_dkad042-B27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.05.018","article-title":"Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii","volume":"136","author":"Jaruratanasirikul","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"2023070503450661500_dkad042-B28","author":"Abouelhassan","year":"2022"},{"key":"2023070503450661500_dkad042-B29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"2023070503450661500_dkad042-B30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052349","article-title":"Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients","volume":"7","author":"Shields","year":"2012","journal-title":"PLoS ONE"},{"key":"2023070503450661500_dkad042-B31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ijantimicag.2009.07.006","article-title":"Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections","volume":"34","author":"Erbay","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"2023070503450661500_dkad042-B32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/jac\/dkl499","article-title":"Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia","volume":"59","author":"Kwon","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2023070503450661500_dkad042-B33","doi-asserted-by":"crossref","first-page":"O1028","DOI":"10.1111\/1469-0691.12716","article-title":"A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia","volume":"20","author":"Nutman","year":"2014","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/4\/1034\/50800340\/dkad042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/4\/1034\/50800340\/dkad042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T23:56:14Z","timestamp":1688514974000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/4\/1034\/7069111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,3,3]]},"published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad042","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,4]]},"published":{"date-parts":[[2023,3,3]]}}}